They reported flawlessly, obviously someone messed something up pretty bad with the vials. Peregrine has the only Super Docetaxel drug out there....haha not really. The conference call confirmed efficacy of Bavi by performing as expected, comparing it to the stellar phase 2 data. Just so happens that Bavi was pumped into the control group as well. This ruined the trial by eliminating the control group, but Docetaxel has been used in a pile of other studies, and it's a very big pile. The FDA knows MOS for Docetaxel control groups and they also know they aren't dealing with a highly toxic treatment plan with Bavi. The FDA has not removed "fast track" status for this study either. It's likely dead, but that has not been concluded yet.
Your not going to get you're update until it is complete. Quit crying. If you want to know so bad, you may as well call up the IDMC and get the info from them, because Peregrine doesn't have this so called update that you think exists. I have dumb employees that work for me, but at least when I tell them they'll know when I know, they get quit playing that broken record. You have to wait...if ya can't handle that, stay the he11 away from biotech.
Dr Pepper and others seem to be hung up on some childishly perceived notion that complete trial data should be released prior to the conclusion of a trial. WRONG! It would be highly unethical to release full figured results during a first look in PR. The press release was done flawlessly and Peregrine continues to flaunt the link to it on their home page. Acting like you are stomping your feet and throwing a fit because you think you found a new angle of attack to post on a message board just makes you look less credible. Stick to managements paychecks/bonus' because that's about the only angle you got.
Why are you here? Do gooders volunteer at soup kitchens and fire halls to help others. Do you really think people believe you are here to right the wrongs of investors? Please. At this moment, there's nothing left to bash. But you continue to try as if it has impact on something other than your own pocket. Titling yourself as a doctor on a biotech forum proves you have no modesty and that you wish your opinion to count, even though it doesn't to me. Again, why are you investing so much of your time on a message board for a start up biotech company? Don't you have lives to save or dogs to neuter, or baskets to weave??? Ooops, titles aren't always what they seem to be are they?
This is a very fair question that applies to every bio tech. A rating system should be set up by the FDA that grades these bio techs based on their practices and historical results against control groups. Instead of allowing study results to slowly decay away into the piles of failures, it can never be erased from the grading system. The system should also be set up to follow CEO's, CFO's, Directors, Board Members, Mergers, ect. This will clean up the clowns in this industry by carrying takeover target grading systems into the acquiring parties grade. Allowing industry "experts" and "professionals" to operate bio techs with high school student or below expectations for experimental study practices needs to stop!
I like to see some thinkers on these boards. Why would someone continue to bash a stock in which they are not personally invested in on the long or the short? Disgruntled ex employee is a possibility, however when you compare the time of day they post, and post often, they are either still unemployed after years. By now, their unemployment would have ran out and they would not have internet access. I believe these people are paid by other pharmaceutical companies, investment firms, or hedge funds. They never refer to stock market technicals on any scale....micro, macro, charting, etc. So I highly doubt they are top level players. Let's say I owned a million shares of Bristol-Meyers. I really wouldn't want something to hit the market that will compete with Opdivo, so I find someone willing to make posts on message boards to bash any and all potential competition. I'd make sure they have no idea why I requested them to do that, but as long as they get paid for it, they'll keep doing it. There's always the off chance these bashers lost as longs in the past with PPHM, but as long as some of them have been posting, holy cow...they had to lose a pile for this to be the case.
I'll be joining you soon. If the bashers have it their way, a reverse split is what they are banking on. The valuation of Avid alone could support the minimum bid requirement. It's close, but a possibility. I think there will be more information pertaining to the Sunrise trial and other chemo combo trials before the first 180 day delisting deadline. They have already told us the Bavituximab/Docetaxel combo performed as expected (which means it followed suite of the phase II study and doubled MOS rates over the before seen results of the control arm Docetaxel only. The problem with the Sunrise trial is the control group, Docetaxel/Placebo also doubled MOS rates. They didn't officially say that it doubled MOS rates, but they did say the control arm was "way off the charts" and "never before seen data". If the chemo/combination trials resume after their internal investigation, or if the FDA were to approve anything, delisting won't be in the cards.
Patients received something that doubled their MOS rate and it came from Peregrine. They have something pretty darn impressive. Super Docetaxel or Bavituximab are the only two options, and one of them is ridiculous.
The bavituximab chemotherapy combination is not off the table. This could be the "other opportunity" reference. If I had to guess, the IDMC recommended the pause sometime in late December or early January. This is when the enroll now link on Peregrines website quit working. I'd also guess the 33% patient death target was hit in late December or early January as well. We know that 90% of patients were enrolled by December 2015 as well. This means at least 60% of the patient population was enrolled by June of 2015 if not earlier. I think 60% is the new patient death target that will tell us a lot more in terms of what happened during this trial. They will know with absolute certainty if all patients received the Bavi + Doce arm and no patients received the control arm. The data should be available within the next few months.
No pharmaceutical company ever answers what you think should be answered in a conference call. They may release total number of enrollees, but they aren't going to break down the data based on geographical location during the conference call. The trial data is still coming in. The enrolling centers were identified on their website. Fuerstein can't navigate a website.
Sshhh...don't be a spoiler. It's always good to be aware of things like that when no one else is. Some people may want to take advantage of this situation.
You sound scared. God forbid they develop the business and make a profit some day. I bet it feels like your days of bashing are numbered. Denial is tough for everyone.
The press release stated it would also be used to manufacture late phase III clinical and commercial production of biologics. Avid is worth a lot more than what meets the eye.
Proven highly effective in multiple trials for breast and lung cancer. I suppose the FDA & AZN are clueless to the mastermind King. Gimme a break...I can't give King that much credit, but it's funny how you do when it suits your cause. The Fool has the same credibility as Jim Cramer & IHUB. The author of the Fool article is no different than Cramer, if they pump it, you better dump it and vice versa. Always very short sighted plays on both their parts and yours.
I'll give one to the bashers: With all the practice King has had, he outta be smarter now a days. Anyway, I thought they gave a lot of information away during the last conference call...much more than I would expect for that type of news. I do have credibility concerns with the FDA & Peregrine. Would the FDA be willing to compare data from previously conducted trials using Docetaxel only? Will the FDA accept future trial designs from Peregrine? The challenge the FDA faces is the upcoming new therapies and how the studies are conducted. 10 years ago, most studies could be conducted in a year or less. This is because the MOS was 8-12 weeks. Now, the FDA continues to follow those old designs and patients have to wait for years, because the MOS for Bavituximab is 50 weeks. If they continue to follow these old standards for toxic chemicals that extend life expectancy by a few months, how can they use those same standards for almost non existent toxicity drugs like Bavi that double over current life expectancies? So 20 years from now, when even more amazing drugs that increase MOS by years instead of weeks or months, it'll take 5-10 years to complete a single phase of study. The FDA will have to modify its guidelines at some point in the future. One has to wonder if the future is now.
It takes a considerable percentage of short shares to create a squeeze. If the news is good, the price jump will be a revaluation set by brokerage firms. Stock acquisition by institutions is the big catalyst.
Assuming a full rate of return on 3 years (which is very good) and not factoring any future growth what so ever, I would agree with the $100 million value for Avid. Based on current market cap, the stock price is undervalued.